The American College of Cardiology (ACC) has launched a document summarizing the potential implications of the new coronavirus identified in Wuhan, China. This new virus has been called COVID-19 by the WHO. According to the WHO reports, there are around 93000 confirmed cases across the world, and around 12600 are outside China. In Latin America,…
TAVR: Should Transradial Approach be the Second Access Site?
Courtesy of Dr. Carlos Fava. One of the major challenges we interventional cardiologists still face is access management. Reduced device diameter and improved transcatheter closure, together with increased operator experience, have significantly reduced vascular complications. However, we shouldn’t lose sight of the secondary access, usually transfemoral, generally used in case of primary access site related…
Chronic Coronary Syndromes Nowadays
Multiple drugs and treatment strategies have emerged in recent years to change significantly the prognosis of patients who suffer from stable chronic angina or, in terms of the latest guidelines, “chronic coronary syndromes.” This semantic change may seem of little importance, but it is intended to remind us that these are not stable patients, but…
Onyx ONE: More Options for Patients at High Risk for Bleeding
Since November 2015, when the LEADERS FREE was published in NEJM, polymer-free drug coated stents had undoubtedly been the best treatment for patients at high risk of bleeding. The benefit was owed to the safety and efficacy of the polymer-free biolimus coated stent (also called umirolimus) vs. bare metal stents in the context of just…
Repeat Revascularization Is Not Benign, at Least in Left Main Disease
After the “EXCEL scandal” at the end of last year, study investigators have been publishing explanations and sub-studies that were planned from the beginning, but which can still be interpreted as explanations. This sub-study states that revascularization was more common in the angioplasty arm, but only revascularizations performed on the target lesion, regardless of the…
Routine Continuous Monitoring After Angioplasty Might Not Be Necessary
According to a recent study published in Circ. Cardiovasc Interv, after a scheduled angioplasty, the rate of arrhythmia requiring some kind of treatment is very low, low enough to deem unnecessary the routine monitoring of all patients. The standard policy at many institutions is continuous cardiac monitoring for several hours after undergoing coronary angioplasty, with…
Reliability of FFR in Patients with Diabetes: Are Other Parameters Necessary?
Diabetes does not seem to alter the results of a fractional flow reserve (FFR) measurement in a given lesion. Recently, expert opinions and small studies had questioned the reliability of FFR in this specific patient subgroup. This new observational study soon to be published in JAMA vanquishes all doubts and confirms the efficacy of this…
FFR in the Time of ISCHEMIA
The results of this great multicenter “real-life” registry are similar to those of randomized clinical trials that studied fractional flow reserve (FFR). Lesion deferral based on FFR is a very safe strategy, even for lesions located in the proximal anterior descending artery. Randomized controlled studies FAME and DEFER convincingly showed the safety of lesion revascularization…
Chronic Inflammation, Coronary Artery Disease and Cancer: Same Coin, Different Sides
Low grade inflammation shown by elevated plasma concentrations of high-sensitive C-reactive protein are a risk factor for coronary artery disease (CAD) patients. There is also evidence to support low grade inflammation could be related to higher risk of cancer. This prospective study evaluated the relation between low grade systemic inflammation and the risk of cancer in…
Impella: A Revolutionary Device Being Questioned
Observational studies (with their subsequent limitations) show a possible increase in adverse events and costs with the use of the Impella device. Two large observational studies stirred doubts regarding the good performance of new circulatory support devices in real-world daily clinical practice. There were more adverse events, including in-hospital death and major bleeding, and more…
Soon after the EXCEL “Scandal” the NOBLE 5-year Outcomes Come Out: Mere Coincidence?
There is no such thing as coincidence, at least not for the evidence-based medical science. This is what the NOBLE 5-year outcomes, soon to be published in the Lancet, seem to say, in line with the BBC exposé of the EXCEL study. The NOBLE study randomized patients with left main disease to compare PCI vs…